Cyclo Therapeutics, Inc.
CYTH · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | -0.04 | 0.06 | 0.08 |
| FCF Yield | -53.12% | -11.20% | -15.90% | -10.87% |
| EV / EBITDA | -4.10 | -6.43 | -7.16 | -5.56 |
| Quality | ||||
| ROIC | 653.70% | 265.10% | -400.70% | -82.97% |
| Gross Margin | 92.81% | -656.37% | -313.18% | -181.49% |
| Cash Conversion Ratio | 0.93 | 0.64 | 1.42 | 0.76 |
| Growth | ||||
| Revenue 3-Year CAGR | -21.12% | -13.10% | -7.48% | -12.12% |
| Free Cash Flow Growth | -212.89% | 37.75% | -43.86% | -6.34% |
| Safety | ||||
| Net Debt / EBITDA | -1.36 | -0.33 | 0.46 | 1.46 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.07 | 3.86 | 3.45 | 3.45 |
| Cash Conversion Cycle | -25,575.36 | -288.56 | -337.14 | -437.16 |